2025-12-31 - Analysis Report
Here's a comprehensive analysis of TransMedics Group Inc. (TMDX), incorporating the provided data:

**0. Simple Numbers & Analysis**

*   **TMDX Cumulative Return:** 200.07%
*   **VOO (S&P 500) Cumulative Return:** 77.45%
*   **TMDX Divergence from VOO:** 127.2 (Relative divergence: 62.7)
*   **Current Price:** \$121.92
*   **5-day SMA:** 124.87
*   **20-day SMA:** 129.29
*   **60-day SMA:** 126.02
*   **RSI:** 30.61
*   **PPO:** -0.74
*   **Market Risk Indicator (MRI):** 0.9
*   **Expected Return (%):** 53.3%
*   **Analyst Consensus:** Buy (Mean: 1.67)
*   **Target Price (avg/high/low):** \$144.73 / \$170.00 / \$114.00

**1. Return Rate Comparison & Alpha/Beta Analysis**

*   **Company Overview:** TransMedics Group Inc. is a medical technology company focused on preserving organs for transplantation.
*   **Return Rate vs. S&P 500 (VOO):** TMDX has significantly outperformed the S&P 500, with a cumulative return of 200.07% compared to VOO's 77.45%.
*   **Divergence:** The divergence of 127.2 indicates TMDX's substantial outperformance. The relative divergence of 62.7 suggests that while significant, the current outperformance isn't at the absolute peak compared to its historical range against the S&P 500.

**Alpha/Beta Analysis:**

| Year       | CAGR     | MDD   | Alpha   | Beta   | Cap(B) |
|------------|----------|-------|---------|--------|--------|
| 2019-2021  | -18.0%   | 83.5% | -61.0%  | -0.0   | 0.7    |
| 2020-2022  | 94.0%    | 83.5% | 95.0%   | 0.0    | 2.1    |
| 2021-2023  | 65.0%    | 80.5% | 64.0%   | 0.1    | 2.7    |
| 2022-2024  | 130.0%   | 85.5% | 109.0%  | 0.1    | 2.1    |
| 2023-2025  | 121.0%   | 85.5% | 54.0%   | 0.3    | 4.2    |

*   **Alpha:**  The Alpha values are consistently positive, indicating TMDX's ability to generate returns above and beyond what would be expected based on market movements alone.  Alpha values show a decline in the most recent year, though still remain positive.
*   **Beta:** The Beta values are low (around 0), suggesting TMDX's price is not highly correlated with the overall market. This could indicate that company-specific factors are driving its performance more than broad market trends.
*   **MDD:** High Maximum Drawdown (MDD) values (all above 80%) highlight the significant volatility and potential for large price declines.
*   **CAGR:** The strong Compound Annual Growth Rate (CAGR) over different periods reflect periods of strong growth, but should be viewed in context with the large MDD values.
*    **Cap(B)** The Market Cap increases from 2019, peaking in 2023 and declining thereafter.

**2. Recent Stock Price Fluctuations**

*   **Price Movement:** The price has recently decreased slightly (`change`: -1.01).
*   **Moving Averages:** The 5-day SMA is below the 20-day SMA, which is slightly above the 60-day SMA. This suggests a potential short-term downtrend.

**3. Indicator Analysis**

*   **Market Risk Indicator (MRI):** A high MRI of 0.9 suggests a medium investment recommendation, indicating that the stock is not considered excessively risky.
*   **RSI:** The RSI of 30.61 indicates that the stock is nearing oversold conditions, which could signal a potential buying opportunity.
*   **PPO:** The PPO of -0.74 suggests a slight downtrend.
*   **Hybrid Signal:** "cash_0%_Buy 100% of cash (7 shares - Very Safe - MRI:0.90)" - The Hybrid Signal is recommending to buy.
*   **Recent Divergence Change:** "Recent (20 days) relative divergence change = 1.1 (+): 단기상승" - This suggests a recent short-term increase in relative divergence from the comparison stock.
*   **Expected Return:** A high expected return of 53.3% suggests potential for significant gains if held long-term.

**4. Recent News & Significant Events**

The recent news articles paint a generally positive picture of TransMedics:

*   **Upgraded Stock Rating:** An upgraded stock rating by Wall Street Zen suggests increased confidence in the company's prospects.
*   **Strong Growth Stock:** Several articles highlight TMDX as a strong growth stock, citing its potential and performance.
*   **Analyst Estimates:** One article estimates significant upside potential (nearly 150%) by the end of 2028.
*   **New Hires & Stock Options:** New hires with stock options and units suggest confidence in the company's future and incentivize long-term performance.

**4-2) Analyst Opinions**

*   **Consensus:** Strong Buy rating indicates that analysts are very positive about the stock's potential.
*   **Target Price:** The average target price of \$144.73 suggests significant upside potential from the current price.

**5. Comprehensive Analysis**

TransMedics (TMDX) has significantly outperformed the S&P 500, showcasing strong growth and potential.  The company's innovative approach to organ preservation seems to be resonating with investors, and analysts are generally optimistic, evidenced by the "Buy" consensus and positive news coverage.

**However, there are also risks to consider:**

*   **Volatility:** High MDD values demonstrate significant price volatility.
*   **Recent Downtrend:** The recent price decrease and moving average trends suggest a potential short-term downtrend.
*   **Beta:** A low beta may indicate that the stock is less correlated with the broader market, leading to unpredictable, company-specific risks.

**Overall:**

* TMDX appears to be a promising growth stock with a strong outlook.
* It's critical to acknowledge the stock's inherent volatility and potential for sharp declines.
* Conduct further due diligence and consider your own risk tolerance before investing.



**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.